NiKang Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NiKang Therapeutics, Inc.
The drug maker announced Phase III results for the HIF-2α inhibitor in renal cell carcinoma patients with disease progression following PD-1/PD-L1 and anti-VEGF therapy.
Four Chinese biotech companies reach in- and out-licensing deals covering antibody drug conjugates, small molecules and vaccines as they continue to pursue and develop innovation.
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.